Spun out of the Fred Hutchinson Cancer Research Center, Presage Biosciences, Inc., fka Presage Therapeutics, is a biotechnology company developing a device that would allow oncologists to test potentially harmful compounds in tiny amounts before giving patients a full dose. Using early human efficacy data in drug development with its patented CIVO arrayed microinjection platform allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor to assess efficacy, resistance, and drug synergies. Presage partners with oncology-focused pharmaceutical companies through strategic alliances to provide in vivo data to validate novel targets, promote drug candidates to the right indiciations, and discover effective drug combinations in drug development situations where it wouldotherwise be impractical or impossible to obtain. Presage is also actively pursuing drug compounds to in-license and is using CIVO to develop a portfolio of promising oncology therapies to advance to the clinic.
